



Universiteit
Leiden
The Netherlands

Chemical biology studies on retaining α -glucosidases

Su, Q.

Citation

Su, Q. (2024, November 6). *Chemical biology studies on retaining α -glucosidases*. Retrieved from <https://hdl.handle.net/1887/4107652>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4107652>

Note: To cite this publication please use the final published version (if applicable).

Chapter 1


General introduction

Glycosphingolipids

Glycosphingolipids (GSLs) are essential structural components of mammalian cell membranes and play a role in many (patho)physiological processes including cellular signaling, cell adhesion/recognition processes, and modulation of signal transduction processes.¹ Glycosphingolipids are composed of carbohydrates linked to the 1-hydroxyl group of ceramide (**1**) which itself consists of a sphingoid base which is *N*-acylated with a fatty acid (see Scheme 1). The most abundant sphingoid base in mammals is sphingosine (**2**) containing 18 carbons and one double bond (d18:1), while sphingoid bases encompassing 12 to 26 carbons also exist.¹ Of all mammalian GSLs, over 90% are derived from glucosylceramide (GlcCer, **3**, also known as glucocerebroside), while the remainder is derived from galactosylceramide (GalCer).^{2,3}

The first step in the biosynthesis of ceramide (**1**), the precursor from which GlcCer is formed, comprises^{1,3} (Scheme 1) condensation of the amino acid L-serine and an acyl-CoA thioester (usually palmitoyl-CoA) into 3-ketosphinganine. The resultant 3-ketosphinganine is then reduced into sphinganine, acylation of which gives dihydroceramide, and desaturation then gives ceramide. After completing its synthesis at the cytosolic side of the ER membrane, ceramide **1** is transported to the cytosolic side of the cis-Golgi apparatus membrane where it is transformed into GlcCer **3** by the membrane bound glucosylceramide synthase⁴ (GCS) using UDP-glucose as the donor glycoside. The synthesized GlcCer **3** is then transported to the luminal side of the Golgi membrane, where it is galactosylated to form lactosylceramide (LacCer). LacCer is an important branching point from which a series of complex glycosphingolipids such as the gangliosides, neolactosides, and lactosides are synthesized by stepwise elongation with various monosaccharides.

In humans, the catabolism of GlcCer (**3**) is mainly mediated by the lysosomal retaining exo- β -glucosidase, GBA1. The resultant ceramide **1** is further processed into sphingosine **2** and a free fatty acid by acid ceramidase (ASAH1) inside the lysosome. The generated sphingosine is exported from lysosomes and can be reused in the cytosol for regenerating ceramide via the salvage pathway.



Scheme 1. A brief schematic representation of GSLs biosynthesis and catabolism. Metabolic enzymes in blue.

Mammalian cells may contain several retaining exo- β -glucosidases. All cells express the lysosomal GBA1, many cell types express the cytosol-facing membrane-associated GBA2 and specific cells express the cytosolic GBA3. These retaining β -glucosidases all hydrolyze GlcCer **3** through a Koshland double displacement mechanism, which involves the formation of a covalent glucosyl enzyme intermediate.⁵ The hydrolysis process (Figure 1) commences with attack of the nucleophilic carboxylic acid residue towards the substrate anomeric center, while simultaneously the catalytic acid/base protonates the aglycon, thereby making it a better leaving group. As the result, an intermediate of covalent glycosyl-enzyme adduct is formed with inversion of the anomeric configuration of the substrate glycoside. The aglycon then leaves the enzyme active site, generating space for a water molecule to enter. In a reversal of steps, the covalent enzyme-substrate intermediate is then hydrolyzed, during which the water molecule is deprotonated by the catalytic acid-base residue. The stereochemistry at the anomeric position of the glucose moiety is again inverted, resulting in a net retention of anomeric stereochemistry.⁶⁻⁸ In this process, the substrate β -glucopyranoside adopts a 1S_3 skew-boat conformation in the initial Michaelis complex with the enzyme active site, placing the aglycon in an axial position allowing for ensuing nucleophilic displacement. During this first S_N2 displacement, the sugar is distorted to a 4H_3 half-chair transition state (TS) conformation from which after formation of the covalent enzyme-substrate acylal adduct the pyranose conformation turns to 4C_1 .^{9,10} Notably, retaining β -glucosidases have the intrinsic capacity to transfer glucose from their substrate to water (giving hydrolysis process A of Figure 1), but also to other acceptor alcohols, leading to an overall transglycosylation event. For instance, GBA1 as well as GBA2 has been shown to be able to transfer glucose from GlcCer to cholesterol (see Figure 1 process B) to give, also with net retention of anomeric configuration, cholesterol β -glucoside as the transglycosylation product.¹¹




Figure 1. Koshland double-replacement catalytic mechanism of retaining β -glucosidases. Process A: hydrolysis, process B: transglycosylation.

Gaucher disease, a common lysosomal storage disorder caused by genetic deficiency in GBA1

Lysosomal storage disorders (LSDs) are rare inherited metabolic disorders that are caused by dysfunction of specific lysosomal metabolic processes.¹²⁻¹⁵ Lysosome dysfunction may result from defects in the formation or stability of lysosomes, export of degradation products or defects in specific enzymatic activities. Often, dysfunction of lysosomes is caused by the mutation of a gene encoding a specific glycosidase that is responsible for the hydrolysis of substrates inside lysosomes, or that of related lysosomal activator proteins, lysosomal transporters, or integral membrane proteins.

Gaucher disease (GD) is the most common LSD,¹⁶ and was first described by Phillippe C. E. Gaucher, who in his doctoral thesis described a patient with an unexplained hepatosplenomegaly in 1882. GD is caused by genetic deficiency in lysosomal acid β -glucosidase GBA1 (Enzyme Commission (EC) number 3.2.1.45), resulting in accumulation of GlcCer (**3**) in lysosomes of tissue macrophages that then transform into lipid-laden Gaucher cells. As a consequence of accumulating GlcCer, also

glucosylsphingosine (GlcSph **4**) levels increase through the action of acid ceramidase (Scheme 1),^{16,17} and GlcSph, which is present in very low levels in healthy individuals, is now viewed as a valuable GD biomarker.¹⁸ GD storage macrophages are thought to underlie characteristic symptoms of GD patients such as hepatosplenomegaly and pancytopenia (shortage of red blood cells and platelets). GD has an average frequency of 1 in 50,000–200,000 births and occurs at a much higher frequency among the Ashkenazi Jewish population (1:1,000).¹²

The clinical phenotype of GD patients is heterogenous, even in some cases of homozygotic twins.¹⁹ The common visceral symptoms include hepatosplenomegaly, thrombocytopenia, abnormalities in coagulation, anemia, and skeletal manifestations (for instance, bone pain and bone fractures). Three different clinical types of this disorder are generally discerned. Type I GD is the most common form. This chronic non-neurological phenotype is characterized by organomegaly, bone disease (for instance, avascular necrosis, bone pain) and cytopenia. Type II GD patients show acute neurological manifestations already in the first year of life, while type III GD patients develop sub-acute, progressive neurological symptoms at a later age. The distinction of GD in these three phenotypes is not very strict and nowadays the existence of a continuum of phenotypes is proposed.²⁰

Therapeutic strategies to treat GD

There has been considerable progress in the development of therapeutic strategies to treat GD in the past decades, making GD perhaps the best-studied LSD from a clinical perspective. Yet, no curative treatment for this disease exist and as well neuropathological (type II , III) manifestations of the disease are difficult to treat by any of the developed therapies.^{12,14,21,22} Two therapeutic strategies are clinical practice and comprise enzyme replacement therapy (ERT) and substrate reduction therapy (SRT). Besides these, several alternative strategies are in (pre)clinical experimental phases, including pharmacological chaperone therapy (PCT). The concept of ERT is to complement endogenous, defective enzyme with a functional, recombinant one.¹⁶ Macrophages, including GD cells, express mannose receptors on the surface, which can be utilized to bind high-mannose type N-glycans in recombinant GBA1 which are then delivered to lysosomes. ERT has been approved for GD by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The available therapeutic enzymes include Imiglucerase²³, Velaglucerase alfa²⁴, and Taliglucerase alfa.²⁵ ERT is however effective only for the non-neuronopathic phenotype (type I) and does not prevent neurological symptoms in patients with types II and III, this because recombinant enzyme is unable to penetrate into the brain. The concept of SRT is to use small molecules to inhibit the build-up of storage molecules in lysosomes by (partially) blocking their biosynthesis.¹⁶ In the context of GD, the registered small-molecule drugs imiglustat and eliglustat, both glucosylceramide synthase (GCS) inhibitors, have been approved for the treatment of type I Gaucher disease.²⁶ SRT drugs have the advantage over recombinant enzymes (which are administered intravenously) that they are oral medications. However, small compound SRT drugs have a slower onset of efficacy than ERT. The concept of PCT is to use small molecules to improve the folding of misfolded protein in patients.²⁷ These small molecules (named pharmacological chaperones) can favorably interact with mutant proteins by assisting folding in the ER. In an alternative version merging PCT with ERT, small molecule pharmacological chaperones are used to stabilize recombinant enzyme in circulation, thereby elevating protein levels that end up in disease tissue.¹⁶ Migalastat as a competitive inhibitor of α -galactosidase A is the first approved PCT drug by the FDA,²⁸ but there is no approved PCT drug for GD at present. Other therapies in development include gene therapy, both *in vivo* transduction (termed AAV therapy) and *ex vivo* transduction (termed lentiviral gene therapy).^{12,21,22}




Figure 2. Therapeutic strategies to treat GD.

Properties of retaining exo- β -glucosidases in human cells

Human cells contain four reported retaining exo- β -glucosidases. The lysosomal acid β -glucosidase GBA1 (glucosylceramidase; glucocerebrosidase; GCase, EC. 3.2.1.45, GH30), is encoded by the *GBA1* gene located on locus 1q21 of the human chromosome 1. GBA1 is a 497 amino acid glycoprotein with four N-linked glycans and has a characteristic $(\alpha/\beta)_8$ TIM barrel catalytic domain.³⁰ In this domain, Glu 340 and Glu 235 are employed as catalytic nucleophile and acid/base residues.³¹ Nascent GBA1 that emerges from ER-associated ribosomal protein synthesis undergoes N-glycosylation to yield, within the ER lumen, newly formed glycoprotein featuring three to four high mannose-type N-glycans. After proceeding through the ER quality control system (the calnexin-calreticulin cycle) and the Golgi apparatus, at which stage three of the high-mannose-type N-glycans are trimmed and reglycosylated to yield complex N-glycans, the GBA1 protein is shuttled to lysosomes by means of the mannose 6-phosphate independent receptor. During this process, GBA1 associates with the lysosomal integral membrane protein 2 (LIMP2) chaperone, from which it detaches once in the acidic environment of lysosomes.³² GBA1 has an optimal catalytic activity at around pH 5.2 *ex vivo*³³ and requires the sphingolipid activator protein, saposin C, to hydrolyze GlcCer located in the lysosomal membrane.³⁴ As described above, deficiency of GBA1 as caused by inherited mutations of the *GBA1* gene are at the basis of GD. Of note, clinical and genetic evidence has shown that GBA1 mutations are also a risk factor for the development of Parkinson Disease.^{35,36}

The non-lysosomal β -glucosidase GBA2 (EC 3.2.1.45, GH116) is thought to locate closely to the cell plasma membrane³⁷ and on the cytosolic surface of the ER and Golgi apparatus.³⁸ It is a protein encompassing 927 amino acids and is encoded by the *GBA2* gene located on human chromosome 9 at position p13.3.³⁹ The enzyme employs E527 as catalytic nucleophile and D677 as acid/base and a retaining mechanism in catalyzing β -glucoside hydrolysis.³¹ *Ex vivo*, GBA2 shows an optimal hydrolysis ability at around pH 5.8.⁴⁰ In humans, GBA2 is mainly expressed in brain, heart, skeletal muscle, kidney and placenta and at lower levels also in liver, spleen, small intestine and lung. GBA2 has been considered to play a compensatory role in GD through hydrolysis of accumulating GlcCer. GBA1 deficient mice and cells from GD patients show elevated GBA2 levels as well as an increase in *in vitro* GBA2 activity.^{41,42} The action of GBA2 in GBA1 deficient GD patients may actually be harmful and inhibition of GBA2 may be beneficial. GBA2 deletion in type I GD mice has been reported to rescue the disease phenotype, despite an increase in GlcCer and GlcSph levels.⁴³ The mechanism for the observed beneficial action of GBA2 deletion in GD mice is not fully understood yet. Mutations in GBA2 have furthermore been associated with spastic paraplegia and cerebellar ataxia.⁴⁴⁻⁴⁶

The cytosolic β -glucosidase GBA3 (EC 3.2.1.21, GH1), also referred as non-specific β -glucosidase, broad-specificity β -glycosidase, and Klotho related protein (KLrP), is a retaining β -glucosidase composed of 469 amino acid and having a broad substrate specificity.⁴⁷ GBA3 is encoded by the *GBA3* gene located in locus 4p15.2, and is expressed as cytosolic protein in human liver, kidney, intestine, and spleen. GBA3 employs E373 as catalytic nucleophile and E165 as catalytic acid/base^{31,48} and has an optimum pH at around 6 to 7. It has been reported that GBA3 can efficiently hydrolyze the artificial C6-NBD-GlcCer but natural GlcCer only at a very low rate.⁴⁹ Besides β -glucosides, GBA3 is also able to hydrolyze β -D-galactosides, β -D-fucosides, α -L-arabinosides and β -D-xylosides. However, the endogenous substrates of GBA3 in human are not known. Beyond GBA1, GBA2 and GBA3, intestinal lactase-phlorizin hydrolase (LPH, EC 3.2.1.23/62, GH1) exclusively found on the brush border of the mammalian small intestine, features retaining β -glucosidase activity.⁵⁰⁻⁵² This enzyme was not subject of the research described in this Thesis.

Table 1. General overview of the human retaining exo- β -glucosidases, GBA1, GBA2 and GBA3.

Enzyme	GBA1	GBA2	GBA3
GH family	30	116	1
Sub-cellular localization	lysosome	plasma membrane ³⁷ / cytosolic surface of ER, Golgi ³⁸	cytosol
Tissue distribution	ubiquitous	brain, heart, skeletal muscle, kidney and placenta	liver, kidney, intestine, and spleen
Optimum pH	5.2	5.8	6.0 - 7.0
Additives for activity	additives needed ³³	no additives ⁴⁰	no additives
Gene mutant consequence	Gaucher Disease	Associated with spastic paraplegia and cerebellar ataxia	unknown

Chemical tools for studying retaining exo- β -glucosidases

Over the past decades, a series of chemical tools have been developed for retaining exo- β -glucosidase (activity) detection, inhibition, and visualization, including fluorogenic substrates, inhibitors, and activity-based probes (ABPs).⁵³⁻⁵⁵ The artificial substrate, 4-methylumbelliferyl- β -D-glucopyranoside **5** (4-MU- β -D-Glc) is composed of a glucose and a 4-methylumbelliferone (4-MU)⁵⁶ group (which is non-fluorescent when attached to the sugar). It can be employed to reflect the β -glycosidic bond hydrolysis activity of retaining exo- β -glucosidases through detecting the released, fluorescent 4-MU.





Figure 3. 4-Methylumbelliferyl-β-D-glucopyranoside **5** fluorogenic substrate.


Small molecule β-glucosidase inhibitors have received considerable attention in studying the mechanism and active site residues of retaining β-glucosidases, as well as their potential value for therapeutic application. Conduritol B epoxide (CBE **6**) and cyclophellitol (CP **7**) have been reported as retaining β-glucosidase-selective inhibitors decades ago (see for their chemical structures Figure 4). CBE **6** and CP **7** both are cyclitol epoxides that covalently and irreversibly reacts with the catalytic nucleophile of retaining β-glucosidases.^{57,58} CBE **6** and cyclophellitol **7** are close structural homologues and their mode of action in inhibiting retaining β-glucosidases is very similar. The inactivation involves attack of the catalytic nucleophile at the pseudo-anomeric position, resulting in opening of the epoxide and the formation of a stable and irreversible enzyme-inhibitor ester adduct. This process is facilitated by protonation of the epoxide by the general acid/base residue (Figure 4B). Compared to CBE **6**, CP **7** has an extra methylene, breaking the symmetry inherent to CBE **6**. As a result, and in contrast to CBE **6**, CP **7** has considerable selectivity for retaining beta-glucosidases (note that rotation of CBE over the axis bisecting C3-C4 and C1-C6 yields a close alpha-glucoside analogue, explaining the inhibitory effect of CBE also on retaining α-glucosidases). An important class of competitive GBA1-3 inhibitors are the *N*-alkylated deoxynojirimycins such as *N*-butyl-1-deoxynojirimycin (NB-DNJ, Miglustat, **8**) and *N*-adamantanemethyloxypentyl-deoxynojirimycin (AMP-DNM, **9**), both originally developed as GCS inhibitors that were subsequently shown to be effective GBA2 inhibitors as well.^{61,62} Activity-based probes (ABPs) finally are powerful chemical tools⁶³⁻⁶⁶ to investigate, retaining β-glucosidases *in vitro* (also in cellular extracts), in cells and in living organisms (see Figure 4).⁶⁴⁻⁶⁹ They are composed of a reactive chemical warhead (to react within the enzyme active site to form a covalent and irreversible enzyme-inhibitor adduct), a recognition element (here a glucopyranose-like structural element) and a reporter tag (fluorescent tag or affinity tag for visualization or purification). The design of β-glucosidase ABPs exploits the scaffold of cyclophellitol **7**^{70,71} onto which a reporter (fluorescent or affinity tag) at C8 of cyclophellitol (for GBA1 selectivity) or at the nitrogen atom of cyclophellitol aziridine (for broad-spectrum reactivity towards retaining β-glucosidases) is grafted. C8-modified cyclophellitol ABPs **10** and **11** potently and selectively label GBA1 over the other two human retaining β-glucosidases, GBA2 and GBA3.^{60,72} Selective labelling of GBA1 by these ABPs was observed in all tested lysates, except in those of the small intestine, in which LPH, and fragments thereof, were also found to be modified.⁷² Vocadlo and co-workers designed fluorogenic substrates equipped with a fluorophore at C6 of a β-glucoside, the aglycon of which carried a fluorescence quencher, compounds that proved to be efficient GBA1-selective substrates able to image GBA1 activity *in situ*.⁵⁹ Artola and co-workers generated cyclophellitol-C8-modified inhibitors (**12**, **13**) that proved to be potent and selective GBA1 inhibitors both *in vitro* and *in vivo*.⁶⁰ Considering that the other two retaining β-glucosidases did only accept C8-modified cyclophellitols, cyclophellitol aziridine scaffolds were developed in which the nitrogen atom of the aziridine was utilized to introduce a fluorescent reporter group (Cy5, BODIPY).⁷³ Cyclophellitol aziridine ABPs **14** and **15** proved to be broad-spectrum retaining β-glucosidase ABPs that label, besides GBA1, also GBA2, GBA3, and LPH.^{73,74} These ABPs report on retaining β-glucosidases irrespective of their origin, this due to the result of conservation of the catalytic pockets. This has allowed the study of retaining β-glucosidases in plants,^{75,76} zebrafish (*Danio rerio*),⁶⁰ and mice.^{72,73} At the onset of the

studies presented in this Thesis, however, no mechanism-based, covalent and irreversible inhibitors, and ABPs derived thereof, selective for either GBA2 or GBA3 were known.


(A) CBE and CP




(B) mechanism of inhibition




(C) iminosugar inhibitor



(E) GBA1-selective inhibitor




(D) β -glucosidase ABP:



R (Tags): Cy5, BODIPY, Biotin etc.

Cyclophellitol epoxide ABPs



Cyclophellitol aziridine ABPs





Figure 4. Retaining β -glucosidase inhibitors and ABPs. (A) Structure of CBE 6 and CP 7. (B) Mechanism by means of which cyclophellitol and cyclophellitol aziridine inhibit retaining β -glucosidases. (C) The competitive GBA1-3 inhibitors Miglustat 8 and AMP-DNM 9. (D) Structure of β -glucosidase ABPs. (E) Cyclophellitol-C8-modified GBA1-selective inhibitors 12 and 13.

Thesis outline

The overall aim of the research described in this Thesis was to employ activity-based protein profiling (ABPP) to study retaining β -glucosidases. Part of the research comprises the discovery and application of inhibitors and activity-based probes (ABPs) for each of the three human retaining β -glucosidases, GBA1, GBA2 and GBA3. These studies are complemented by research in which the inhibitors and probes are used to study homologous retaining β -glucosidase activities from other species. **Chapter 2** comprises a study in which three structurally and configurationally closely related cyclitol epoxides and aziridines, namely those derived from conduritol B epoxide, β -D-xylo-cyclophellitol and cyclophellitol, are compared for their activity and selectivity as GBA1 inhibitors and activity-based probes. **Chapter 3** studies β -D-arabinofuranose-configured cyclophellitol aziridine ABPs as selective reporters of mammalian GBA2 activities *in vitro* and *in situ*. **Chapter 4** concerns the exploration of potential GBA3-selective fluorogenic substrates and fluorescent ABPs. **Chapter 5** reports on the use of the established cyclophellitol-based ABPs to probe *Caenorhabditis elegans* (*C. elegans*) samples for β -glucosidase activities and to establish similarities and differences between these and the mammalian enzymes (GBA1, GBA2). **Chapter 6** utilizes the same set of ABPs to study the activity of a putative β -glucosidase (termed B56) from the tobacco plant *Nicotiana tabacum*. **Chapter 7** discusses the results of the experiments described in **Chapters 2-6** and presents some prospects for future research. This thesis is concluded with **Appendices** that include a **list of publications** and a **Curriculum vitae** of the author.

References

1. T. Wennekes, R. J. van den Berg, R. G. Boot, G. A. van der Marel, H. S. Overkleeft, J. M. Aerts, Glycosphingolipids--nature, function, and pharmacological modulation, *Angew. Chem. Int. Ed.* 2009, **48**, 8848-8869.
2. C. A. Lingwood, Glycosphingolipid functions, *Cold Spring Harb. Perspect. Biol.* 2011, **3**, a004788.
3. C. R. Gault, L. M. Obeid, Y. A. Hannun, An overview of sphingolipid metabolism: from synthesis to breakdown, *Sphingolipids as signaling and regulatory molecules* 2010, 1-23.
4. S. Ichikawa, Y. Hirabayashi, Glucosylceramide synthase and glycosphingolipid synthesis, *Trends Cell Biol.*, 1998, **8**, 198-202.
5. D. E. Koshland, Stereochemistry and the mechanism of enzymatic reactions, *Biol. Rev.* 1953, **28**, 416-436.
6. A. Vasella, G. J. Davies, M. Bohm, Glycosidase mechanisms, *Curr. Opin. Chem. Biol.* 2002, **6**, 619-629.
7. D. L. Zechel, S. G. Withers, Glycosidase mechanisms: anatomy of a finely tuned catalyst, *Acc. Chem. Res.* 2000, **33**, 11-18.
8. C. S. Rye, S. G. Withers, Glycosidase mechanisms, *Curr. Opin. Chem. Biol.* 2000, **4**, 573-580.
9. G. J. Davies, A. Planas, C. Rovira, Conformational analyses of the reaction coordinate of glycosidases, *Acc. Chem. Res.* 2012, **45**, 308-316.
10. M. T. C. Walvoort, G. A. van der Marel, H. S. Overkleeft, J. D. C. Codée, On the reactivity and selectivity of donor glycosides in glycochemistry and glycobiology: trapped covalent intermediates, *Chem. Sci.* 2013, **4**, 897-906.
11. A. R. Marques, M. Mirzaian, H. Akiyama, P. Wisse, M. J. Ferraz, P. Gaspar, K. Ghauharali-van der Vlugt, R. Meijer, P. Giraldo, P. Alfonso, P. Irun, M. Dahl, S. Karlsson, E. V. Pavlova, T. M. Cox, S. Scheij, M. Verhoek, R. Ottenhoff, C. P. van Roomen, N. S. Pannu, M. van Eijk, N. Dekker, R. G. Boot, H. S. Overkleeft, E. Blommaart, Y. Hirabayashi, J. M. Aerts, Glucosylated cholesterol in mammalian cells and tissues: formation and degradation by multiple cellular beta-glucosidases, *J. Lipid Res.* 2016, **57**, 451-463.
12. F. M. Platt, A. d'Azzo, B. L. Davidson, E. F. Neufeld, C. J. Tifft, Lysosomal storage diseases, *Nat. Rev. Dis. Primers* 2018, **4**, 27.
13. A. R. A. Marques, P. Saftig, Lysosomal storage disorders - challenges, concepts and avenues for therapy: beyond rare diseases, *J. Cell Sci.* 2019, **132**.
14. G. Parenti, G. Andria, A. Ballabio, Lysosomal storage diseases: from pathophysiology to therapy, *Annu. Rev. Med.* 2015, **66**, 471-486.
15. B. Breiden, K. Sandhoff, Lysosomal glycosphingolipid storage diseases, *Annu. Rev. Biochem.* 2019, **88**, 461-485.
16. J. M. Aerts, C. L. Kuo, L. T. Lelieveld, D. E. C. Boer, M. J. C. van der Lienden, H. S. Overkleeft, M. Artola, Glycosphingolipids and lysosomal storage disorders as illustrated by Gaucher disease, *Curr. Opin. Chem. Biol.* 2019, **53**, 204-215.
17. J. M. Aerts, M. J. Ferraz, M. Mirzaian, P. Gaspar, S. V. Oussoren, P. Wisse, C. L. Kuo, L. T. Lelieveld, K. Kytidou, M. D. Hazeu, D. E. C. Boer, R. Meijer, M. J. C. van der Lienden, D. H. M. Chao, T. L. Gabriel, J. Aten, H. S. Overkleeft, M. van Eijk, R. G. Boot, A. R. A. Marques, *Encyclopedia of Life Sciences* 2017, DOI: 10.1002/9780470015902.a0027592, pp. 1-13.
18. A. Dardis, H. Michelakakis, P. Rozenfeld, K. Fumic, J. Wagner, E. Pavan, M. Fuller, S. Revel-Vilk, D. Hughes, T. Cox, J. M. Aerts, International Working Group of Gaucher, patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1, *Orphanet J. Rare Dis.* 2022, **17**, 442.
19. R. H. Lachmann, I. R. Grant, D. Halsall, T. M. Cox, Twin pairs showing discordance of phenotype in adult Gaucher's disease, *QJM* 2004, **97**, 199-204.
20. E. Sidransky, Gaucher disease: complexity in a "simple" disorder, *Mol. Genet. Metab.* 2004, **83**, 6-15.

21. R. Sam, E. Ryan, E. Daykin, E. Sidransky, Current and emerging pharmacotherapy for Gaucher disease in pediatric populations, *Expert Opin. Pharmacother.* 2021, **22**, 1489-1503.
22. C. Fernandez-Pereira, B. San Millan-Tejado, M. Gallardo-Gomez, T. Perez-Marquez, M. Alves-Villar, C. Melcon-Crespo, J. Fernandez-Martin, S. Ortolano, Therapeutic approaches in lysosomal storage diseases, *Biomolecules* 2021, **11**.
23. Y. Kacher, B. Brumshtein, S. Boldin-Adamsky, L. Toker, A. Shainskaya, I. Silman, J. L. Sussman, A. H. Futerman, Acid beta-glucosidase: insights from structural analysis and relevance to Gaucher disease therapy, *Biol. Chem.* 2008, **389**, 1361-1369.
24. T. A. Burrow, G. A. Grabowski, Velaglucerase alfa in the treatment of Gaucher disease type 1, *Clin. Investig.* 2011, **1**, 285-293.
25. L. van Dussen, A. Zimran, E. M. Akkerman, J. M. Aerts, M. Petakov, D. Elstein, H. Rosenbaum, D. Aviezer, E. Brill-Almon, R. Chertkoff, M. Maas, C. E. Hollak, Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease, *Blood Cells Mol. Dis.* 2013, **50**, 206-211.
26. M. Pineda, M. Walterfang, M. C. Patterson, Miglustat in Niemann-Pick disease type C patients: a review, *Orphanet J. Rare Dis.* 2018, **13**, 140.
27. J. M. Benito, J. M. Garcia Fernandez, C. Ortiz Mellet, Pharmacological chaperone therapy for Gaucher disease: a patent review, *Expert Opin. Ther. Pat.* 2011, **21**, 885-903.
28. A. Markham, Migalastat: first global approval, *Drugs* 2016, **76**, 1147-1152.
29. V. Lombard, H. Golaconda Ramulu, E. Drula, P. M. Coutinho, B. Henrissat, The carbohydrate-active enzymes database (CAZy) in 2013, *Nucleic Acids Res.* 2014, **42**, D490-495.
30. F. Ben Bdira, M. Artola, H. S. Overkleeft, M. Ubbink, J. M. Aerts, Distinguishing the differences in beta-glycosylceramidase folds, dynamics, and actions informs therapeutic uses, *J. Lipid Res.* 2018, **59**, 2262-2276.
31. W. W. Kallemijn, M. D. Witte, T. M. Voorn-Brouwer, M. T. Walvoort, K. Y. Li, J. D. Codée, G. A. van der Marel, R. G. Boot, H. S. Overkleeft, J. M. Aerts, A sensitive gel-based method combining distinct cyclophellitol-based probes for the identification of acid/base residues in human retaining beta-glucosidases, *J. Biol. Chem.* 2014, **289**, 35351-35362.
32. D. Reczek, M. Schwake, J. Schröder, H. Hughes, J. Blanz, X. Jin, W. Brondyk, S. Van Patten, T. Edmunds, P. Saftig, LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase, *Cell* 2007, **131**, 770-783.
33. J. M. Aerts, W. E. Donker-Koopman, M. K. van der Vliet, L. M. Jonsson, E. I. Ginns, G. J. Murray, J. A. Barranger, J. M. Tager, A. W. Schram, The occurrence of two immunologically distinguishable beta-glucocerebrosidases in human spleen, *Eur. J. Biochem.* 1985, **150**, 565-574.
34. R. J. Tamargo, A. Velayati, E. Goldin, E. Sidransky, The role of saposin C in Gaucher disease, *Mol. Genet. Metab.* 2012, **106**, 257-263.
35. E. Aflaki, W. Westbroek, E. Sidransky, The complicated relationship between Gaucher disease and Parkinsonism: insights from a rare disease, *Neuron* 2017, **93**, 737-746.
36. J. Do, C. McKinney, P. Sharma, E. Sidransky, Glucocerebrosidase and its relevance to Parkinson disease, *Mol. Neurodegener.* 2019, **14**, 36.
37. R. G. Boot, M. Verhoek, W. Donker-Koopman, A. Strijland, J. van Marle, H. S. Overkleeft, T. Wennekes, J. M. Aerts, Identification of the non-lysosomal glucosylceramidase as beta-glucosidase 2, *J. Biol. Chem.* 2007, **282**, 1305-1312.
38. H. G. Korschen, Y. Yildiz, D. N. Raju, S. Schonauer, W. Bonigk, V. Jansen, E. Kremmer, U. B. Kaupp, D. Wachten, The non-lysosomal beta-glucosidase GBA2 is a non-integral membrane-associated protein at the endoplasmic reticulum (ER) and Golgi, *J. Biol. Chem.* 2013, **288**, 3381-3393.
39. A. Massimo, S. Maura, L. Nicoletta, M. Giulia, M. Valentina, C. Elena, P. Alessandro, B. Rosaria, S. Sandro, Current and novel aspects on the non-lysosomal beta-glucosylceramidase GBA2, *Neurochem. Res.* 2016, **41**, 210-220.
40. S. van Weely, M. Brandsma, A. Strijland, J. M. Tager, J. M. Aerts, Demonstration of the existence of a second, non-lysosomal glucocerebrosidase that is not deficient in Gaucher disease, *Biochim. Biophys. Acta* 1993, **1181**, 55-62.

41. D. G. Burke, A. A. Rahim, S. N. Waddington, S. Karlsson, I. Enquist, K. Bhatia, A. Mehta, A. Vellodi, S. Heales, Increased glucocerebrosidase (GBA) 2 activity in GBA1 deficient mice brains and in Gaucher leucocytes, *J. Inherit. Metab. Dis.* 2013, **36**, 869-872.
42. Y. Yildiz, P. Hoffmann, S. Vom Dahl, B. Breiden, R. Sandhoff, C. Niederau, M. Horwitz, S. Karlsson, M. Filocamo, D. Elstein, M. Beck, K. Sandhoff, E. Mengel, M. C. Gonzalez, M. M. Nothen, E. Sidransky, A. Zimran, M. Mattheisen, Functional and genetic characterization of the non-lysosomal glucosylceramidase 2 as a modifier for Gaucher disease, *Orphanet J. Rare Dis.* 2013, **8**, 151.
43. P. K. Mistry, J. Liu, L. Sun, W. L. Chuang, T. Yuen, R. Yang, P. Lu, K. Zhang, J. Li, J. Keutzer, A. Stachnik, A. Mennone, J. L. Boyer, D. Jain, R. O. Brady, M. I. New, M. Zaidi, Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease, *Proc. Natl. Acad. Sci. U. S. A.* 2014, **111**, 4934-4939.
44. S. Sultana, J. Stewart, A. C. van der Spoel, Truncated mutants of beta-glucosidase 2 (GBA2) are localized in the mitochondrial matrix and cause mitochondrial fragmentation, *PLoS One* 2020, **15**, e0233856.
45. M. B. Hammer, G. Eleuch-Fayache, L. V. Schottlaender, H. Nehdi, J. R. Gibbs, S. K. Arepalli, S. B. Chong, D. G. Hernandez, A. Sailer, G. Liu, P. K. Mistry, H. Cai, G. Shrader, C. Sassi, Y. Bouhlal, H. Houlden, F. Hentati, R. Amouri, A. B. Singleton, Mutations in GBA2 cause autosomal-recessive cerebellar ataxia with spasticity, *Am. J. Hum. Genet.* 2013, **92**, 245-251.
46. E. Martin, R. Schule, K. Smets, A. Rastetter, A. Boukhris, J. L. Loureiro, M. A. Gonzalez, E. Mundwiler, T. Deconinck, M. Wessner, L. Jornea, A. C. Oteyza, A. Durr, J. J. Martin, L. Schols, C. Mhiri, F. Lamari, S. Zuchner, P. De Jonghe, E. Kabashi, A. Brice, G. Stevanin, Loss of function of glucocerebrosidase GBA2 is responsible for motor neuron defects in hereditary spastic paraplegia, *Am. J. Hum. Genet.* 2013, **92**, 238-244.
47. Y. Hayashi and M. Ito, Klotho-related protein KLRP: structure and functions, *Vitam. Horm.* 2016, **101**, 1-16.
48. Y. Hayashi, N. Okino, Y. Kakuta, T. Shikanai, M. Tani, H. Narimatsu, M. Ito, Klotho-related protein is a novel cytosolic neutral beta-glycosylceramidase, *J. Biol. Chem.* 2007, **282**, 30889-30900.
49. N. Dekker, T. Voorn-Brouwer, M. Verhoek, T. Wennekes, R. S. Narayan, D. Speijer, C. E. Hollak, H. S. Overkleeft, R. G. Boot, J. M. Aerts, The cytosolic beta-glucosidase GBA3 does not influence type 1 Gaucher disease manifestation, *Blood Cells Mol. Dis.* 2011, **46**, 19-26.
50. H. Skovbjerg, H. Sjostrom, O. Noren, Purification and characterisation of amphiphilic lactase/phlorizin hydrolase from human small intestine, *Eur. J. Biochem.* 1981, **114**, 653-661.
51. H. Elferink, J. P. J. Bruekers, G. H. Veeneman, T. J. Boltje, A comprehensive overview of substrate specificity of glycoside hydrolases and transporters in the small intestine : "A gut feeling", *Cell Mol. Life Sci.* 2020, **77**, 4799-4826.
52. H. Wacker, P. Keller, R. Falchetto, G. Legler, G. Semenza, Location of the two catalytic sites in intestinal lactase-phlorizin hydrolase. Comparison with sucrase-isomaltase and with other glycosidases, the membrane anchor of lactase-phlorizin hydrolase, *J. Biol. Chem.* 1992, **267**, 18744-18752.
53. H. M. Burke, T. Gunnlaugsson, E. M. Scanlan, Recent advances in the development of synthetic chemical probes for glycosidase enzymes, *Chem. Commun.* 2015, **51**, 10576-10588.
54. L. Wu, Z. Armstrong, S. P. Schröder, C. de Boer, M. Artola, J. M. Aerts, H. S. Overkleeft, G. J. Davies, An overview of activity-based probes for glycosidases, *Curr. Opin. Chem. Biol.* 2019, **53**, 25-36.
55. M. D. Witte, G. A. van der Marel, J. M. Aerts, H. S. Overkleeft, Irreversible inhibitors and activity-based probes as research tools in chemical glycobiology, *Org. Biomol. Chem.* 2011, **9**, 5908-5926.
56. J. Mead, J. Smith, R. Williams, The biosynthesis of the glucuronides of umbelliferone and 4-methylumbelliferone and their use in fluorimetric determination of β -glucuronidase, *Biochem. J.* 1955, **61**, 569-574.

57. C. L. Kuo, W. W. Kallemeyjn, L. T. Lelieveld, M. Mirzaian, I. Zoutendijk, A. Vardi, A. H. Futerman, A. H. Meijer, H. P. Spaink, H. S. Overkleeft, J. M. Aerts, M. Artola, In vivo inactivation of glycosidases by conduritol B epoxide and cyclophellitol as revealed by activity-based protein profiling, *FEBS J.* 2019, **286**, 584-600.
58. S. Atsumi, K. Umezawa, H. Iinuma, H. Naganawa, H. Nakamura, Y. Iitaka, T. Takeuchi, Production, isolation and structure determination of a novel beta-glucosidase inhibitor, cyclophellitol, from *Phellinus* sp, *J. Antibiot.* 1990, **43**, 49-53.
59. A. K. Yadav, D. L. Shen, X. Shan, X. He, A. R. Kermode, D. J. Vocadlo, Fluorescence-quenched substrates for live cell imaging of human glucocerebrosidase activity, *J. Am. Chem. Soc.* 2015, **137**, 1181-1189.
60. M. Artola, C. L. Kuo, L. T. Lelieveld, R. J. Rowland, G. A. van der Marel, J. D. C. Codée, R. G. Boot, G. J. Davies, J. M. Aerts, H. S. Overkleeft, Functionalized cyclophellitols are selective glucocerebrosidase inhibitors and induce a bona fide neuropathic Gaucher model in zebrafish, *J. Am. Chem. Soc.* 2019, **141**, 4214-4218.
61. H. S. Overkleeft, G. H. Renkema, J. Neele, P. Vianello, I. O. Hung, A. Strijland, A. M. van der Burg, G. J. Koomen, U. K. Pandit, J. M. Aerts, Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase, *J. Biol. Chem.* 1998, **273**, 26522-26527.
62. D. Lahav, B. Liu, R. van den Berg, A. van den Nieuwendijk, T. Wennekes, A. T. Ghisaidoobe, I. Breen, M. J. Ferraz, C. L. Kuo, L. Wu, P. P. Geurink, H. Ovaa, G. A. van der Marel, M. van der Stelt, R. G. Boot, G. J. Davies, J. M. Aerts, H. S. Overkleeft, A fluorescence polarization activity-based protein profiling assay in the discovery of potent, selective inhibitors for human nonlysosomal glucosylceramidase, *J. Am. Chem. Soc.* 2017, **139**, 14192-14197.
63. J. M. Punt, D. van der Vliet, M. van der Stelt, Chemical probes to control and visualize lipid metabolism in the brain, *Acc. Chem. Res.* 2022, **55**, 3205-3217.
64. P. Yang, K. Liu, Activity-based protein profiling: recent advances in probe development and applications, *ChemBioChem* 2015, **16**, 712-724.
65. N. Li, H. S. Overkleeft, B. I. Florea, Activity-based protein profiling: an enabling technology in chemical biology research, *Curr. Opin. Chem. Biol.* 2012, **16**, 227-233.
66. M. B. Nodwell, S. A. Sieber, ABPP methodology: introduction and overview, *Top. Curr. Chem.* 2012, **324**, 1-41.
67. D. Hunerdosse, D. K. Nomura, Activity-based proteomic and metabolomic approaches for understanding metabolism, *Curr. Opin. Biotechnol.* 2014, **28**, 116-126.
68. S. Wang, Y. Tian, M. Wang, M. Wang, G. B. Sun, X. B. Sun, Advanced activity-based protein profiling application strategies for drug development, *Front. Pharmacol.* 2018, **9**, 353.
69. J. Krysiak, R. Breinbauer, in *Activity-Based Protein Profiling*, 2011, DOI: 10.1007/128_2011_289, ch. Chapter 289, pp. 43-84.
70. W. W. Kallemeyjn, M. D. Witte, T. Wennekes, J. M. Aerts, Mechanism-based inhibitors of glycosidases: design and applications, *Adv. Carbohydr. Chem. Biochem.* 2014, **71**, 297-338.
71. L. I. Willems, J. Jiang, K. Y. Li, M. D. Witte, W. W. Kallemeyjn, T. J. Beenakker, S. P. Schröder, J. M. Aerts, G. A. van der Marel, J. D. Codée, H. S. Overkleeft, From covalent glycosidase inhibitors to activity-based glycosidase probes, *Chem. Eur. J.* 2014, **20**, 10864-10872.
72. M. D. Witte, W. W. Kallemeyjn, J. Aten, K. Y. Li, A. Strijland, W. E. Donker-Koopman, A. M. van den Nieuwendijk, B. Bleijlevens, G. Kramer, B. I. Florea, B. Hooibrink, C. E. Hollak, R. Ottenhoff, R. G. Boot, G. A. van der Marel, H. S. Overkleeft, J. M. Aerts, Ultrasensitive in situ visualization of active glucocerebrosidase molecules, *Nat. Chem. Biol.* 2010, **6**, 907-913.
73. W. W. Kallemeyjn, K. Y. Li, M. D. Witte, A. R. Marques, J. Aten, S. Scheij, J. Jiang, L. I. Willems, T. M. Voorn-Brouwer, C. P. van Roomen, R. Ottenhoff, R. G. Boot, H. van den Elst, M. T. Walvoort, B. I. Florea, J. D. Codée, G. A. van der Marel, J. M. Aerts, H. S. Overkleeft, Novel activity-based probes for broad-spectrum profiling of retaining beta-exoglucosidases in situ and in vivo, *Angew. Chem. Int. Ed.* 2012, **51**, 12529-12533.
74. S. P. Schröder, J. W. van de Sande, W. W. Kallemeyjn, C. L. Kuo, M. Artola, E. J. van Rooden, J. Jiang, T. J. M. Beenakker, B. I. Florea, W. A. Offen, G. J. Davies, A. J. Minnaard, J. M. Aerts, J. D.

- C. Codée, G. A. van der Marel, H. S. Overkleeft, Towards broad spectrum activity-based glycosidase probes: synthesis and evaluation of deoxygenated cyclophellitol aziridines, *Chem. Commun.* 2017, **53**, 12528-12531.
75. A. M. Husaini, K. Morimoto, B. Chandrasekar, S. Kelly, F. Kaschani, D. Palmero, J. Jiang, M. Kaiser, O. Ahrazem, H. S. Overkleeft, R. A. L. van der Hoorn, Multiplex fluorescent, activity-based protein profiling identifies active alpha-glycosidases and other hydrolases in plants, *Plant Physiol.* 2018, **177**, 24-37.
76. B. Chandrasekar, T. Colby, A. Emran Khan Emon, J. Jiang, T. N. Hong, J. G. Villamor, A. Harzen, H. S. Overkleeft, R. A. van der Hoorn, Broad-range glycosidase activity profiling, *Mol. Cell. Proteomics* 2014, **13**, 2787-2800.